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Table S2. Lethal and teratogenic effects observed in zebrafish (Danio rerio) embryos at different 
hours post fertilization (hpf). 
Category   Developmental endpoints  Exposure time (hpf) 
    24  48  72  96  
Lethal effect  Egg coagulationa  ● ● ● ● 
  No somite formation  ● ● ● ● 
  Tail not detached  ● ● ● ● 
  No heart-beat   ● ● ● 
Teratogenic effect  Malformation of head  ● ● ● ● 
  Malformation of eyesb  ● ● ● ● 
  Malformation of sacculi/otolithsc  ● ● ● ● 
  Malformation of chorda  ● ● ● ● 
  Malformation of taild  ● ● ● ● 
  Scoliosis  ● ● ● ● 
  Heart beat frequency   ● ● ● 
  Blood circulation   ● ● ● 
  Pericardial edema  ● ● ● ● 
  Yolk edema  ● ● ● ● 
  Yolk deformation  ● ● ● ● 
  Growth retardatione  ● ● ● ● 
a No clear organs structure are recognized 
b Malformation of eyes was recorded for the retardation in eye development and abnormality in shape and size. 
c Presence of no, one or more than two otoliths per sacculus, as well as reduction and enlargement of otoliths and/or sacculi (otic 
vesicles). 
d Tail malformation was recorded when the tail was bent, twisted or shorter than to control embryos as assessed by optical 
comparison. 
e Growth retardation was recorded by comparing with the control embryos in development or size (before hatching, at 24 hpf and 48 
hpf) or in a body length (after hatching, at and onwards 72 hpf) using by optical comparison using a inverted microscope (CKX41; 
Olympus, Tokyo, Japan)
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Notochordb  Eyesb Otolithsb  Pericardial 
edemab 
Yolk   
edemab 











75 µg/ml 10.00 3.33 86.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 96.30 0.00 0.00 3.85 
50 µg/ml 3.33 0.00 96.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 96.55 0.00 0.00 0.00 
25 µg/ml 0.00 0.00 100.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100.00 0.00 0.00 0.00 
10 µg/ml 0.00 0.00 100.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100.00 0.00 0.00 0.00 
5 µg/ml 0.00 0.00 100.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100.00 0.00 0.00 0.00 
1 µg/ml 0.00 0.00 100.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100.00 0.00 0.00 0.00 
16  
75 µg/ml 20.00 80.00 0.00 100.00 0.00 97.92 0.00 52.08 0.00 0.00 0.00 100.00 100.00 97.92 100.00 
50 µg/ml 6.67 1.67 86.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100.00 0.00 1.89 1.89 
25 µg/ml 0.00 1.67 98.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100.00 0.00 1.67 0.00 
10 µg/ml 0.00 0.00 100.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100.00 0.00 0.00 0.00 
5 µg/ml 0.00 0.00 100.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100.00 0.00 0.00 0.00 
1 µg/ml 0.00 0.00 100.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100.00 0.00 0.00 0.00 
23  
75 µg/ml 100.00 0.00 0.00                         
50 µg/ml 33.33 61.67 5.00 0.00 0.00 92.50 0.00 87.50 0.00 0.00 0.00 42.50 100.00 100.00 100.00 
25 µg/ml 20.00 53.33 26.67 0.00 0.00 66.67 0.00 58.33 0.00 0.00 0.00 100.00 66.67 50.00 66.67 
10 µg/ml 3.33 5.00 91.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100.00 0.00 5.17 0.00 
5 µg/ml 0.00 0.00 100.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100.00 0.00 0.00 0.00 
1 µg/ml 0.00 0.00 100.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100.00 0.00 0.00 0.00 
Voriconazole  
75 µg/ml 100.00 0.00 0.00  - -  -  -  -  -  -  -  -  -  -  -  
50 µg/ml 100.00 0.00 0.00  - -  -  -  -  -  -  -  -  -  -  -  
25 µg/ml 100.00 0.00 0.00  - -  -  -  -  -  -  -  -  -  -  -  
10 µg/ml 80.00 20.00 0.00 100.00 0.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 0.00 
5 µg/ml 36.67 63.33 0.00 100.00 0.00 100.00 100.00 100.00 0.00 0.00 0.00 100.00 100.00 94.74 0.00 
1 µg/ml 20.00 60.00 20.00 20.00 100.00 44.44 0.00 55.56 0.00 0.00 0.00 100.00 100.00 55.56 0.00 
Abrevitation used: (-) data not available due to 100% mortality. 
a Percentage of mortality based on all eggs. 
b Percentage of teratogenic effect based on all alive embryos at the time of assessment. 
c Percentage of teratogenic effect based on all alive hatched embryos at the time of assessment.





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































HPLC analyses for purity 
The HPLC analyses were performed in diverse systems: 
 
Method A 
 Zorbax Eclipse Plus C18 4.6 x 150 mm, 1.8 µ, S.N. USWKY01594 was used as the 
stationary phase. The eluent was made from the following solvents: 0.2 % formic acid in water 
(A) and acetonitrile (B). The analysis were performed at the UV max of the compounds (at 270 
nm or 300 nm) to maximize selectivity. The compounds were dissolved in dichloromethane or 
methanol; the final concentrations were ≈ 1 mg ml-1; the flow rate was 0.5 ml min-1.  
 Compounds 7, 9, 10, 11, 12 and 19 were eluted using the gradient protocol: 0 – 0.5 min 
95 % A, 0.5 - 3 min 95 % A → 5 % A, 3 - 13 min  5 % A, 13 – 14 min 5 % A → 95 % A, 14 – 
16 min 95 % A. 
 Compound 21 was eluted using the gradient protocol: 0 – 0.5 min 95 % A, 0.5 - 3 min 95 
% A → 5 % A, 3 - 13 min  5 % A, 13 – 14 min 5 % A → 95 % A, 14 – 16 min 95 % A. 
 
Method B 
 Zorbax Eclipse XDB-C18 4.6 x 50 mm, 1.8 µ, S.N. USWDY02826 was used as the 
stationary phase. The eluent was made from the following solvents: 0.2 % formic acid in water 
(A) and acetonitrile (B). The analysis were performed at the UV max of the compounds (at 270 
nm or 300 nm) to maximize selectivity. The compounds were dissolved in dichloromethane or 
methanol; the final concentrations were ≈ 1 mg ml-1; the flow rate was 0.5 ml min-1. 
 Compounds 7, 9, 10, 11, 12, 19 and 21 were eluted using the gradient protocol: 0 – 0.5 
min 95 % A, 0.5 - 3 min 95 % A → 5 % A, 3 - 13 min  5 % A, 13 – 14 min 5 % A→ 95 % A, 14 
– 16 min 95 % A. 
 
Method C 
 Zorbax Eclipse Plus C18 2.1 x 100 mm, 1.8 µ was used as the stationary phase. The 
eluent was made from the following solvents: 0.2 % formic acid in water (A) and methanol (B). 
The analysis were performed at the UV max of the compounds (254 nm or 270 nm) to maximize 
selectivity. The compounds were dissolved in dichloromethane or methanol; the final 
concentrations were ≈ 1 mg ml-1; the flow rate was 0.2 ml min-1. 
 Compounds 14, 15, 17, 18 and 20 were eluted using the gradient protocol: 0 – 0.5 min 95 
% A, 0.5 - 3 min 95 % A → 5 % A, 3 - 17 min  5 % A, 17 – 19 min 5 % A → 95 % A, 19 – 20 
min 95 % A. 
 
Method D 
 Zorbax Eclipse Plus C18 2.1 x 100 mm, 1.8 µ was used as the stationary phase. Eluent 
was made from the following solvents: 0.2 % formic acid in water (A) and acetonitrile (B). The 
analysis were performed at the UV max of the compounds (254 nm or 270 nm) to maximize 
selectivity. The compounds were dissolved in dichloromethane or methanol; the final 
concentrations were ≈ 1 mg ml-1; the flow rate was 0.2 ml min-1. 
  Compounds 14, 15, 17, 18 and 20 were eluted using gradient protocol: 0 – 0.5 min 95 % 
A, 0.5 - 3 min 95 % A→ 5 % A, 3 - 17 min  5 % A, 17 – 19 min 5 % A→ 95 % A, 19 – 20 min 














































































































HPLC elution profiles for compound 21, upper method A and lower method B 
